Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B−/− (Wilson disease) mice

James P. Hamilton, Lahari Koganti, Abigael Muchenditsi, Venkata S. Pendyala, David Huso, Joseph Hankin, Robert C. Murphy, Dominik Huster, Uta Merle, Christopher Mangels, Nan Yang, James J. Potter, Esteban Mezey, Svetlana Lutsenko – 17 December 2015 – Wilson disease (WD) is a hepatoneurological disorder caused by mutations in the copper‐transporter, ATP7B. Copper accumulation in the liver is a hallmark of WD. Current therapy is based on copper chelation, which decreases the manifestations of liver disease, but often worsens neurological symptoms.

Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy

Christophe Cassinotto, Jérome Boursier, Victor de Lédinghen, Jérome Lebigot, Bruno Lapuyade, Paul Cales, Jean‐Baptiste Hiriart, Sophie Michalak, Brigitte Le Bail, Victoire Cartier, Amaury Mouries, Frédéric Oberti, Isabelle Fouchard‐Hubert, Julien Vergniol, Christophe Aubé – 13 December 2015 – Nonalcoholic fatty liver disease (NAFLD) has become a major public health issue.

Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma

Chuan‐chuan Zhou, Fu Yang, Sheng‐xian Yuan, Jin‐zhao Ma, Feng Liu, Ji‐hang Yuan, Feng‐rui Bi, Kong‐ying Lin, Jian‐hua Yin, Guang‐wen Cao, Wei‐ping Zhou, Fang Wang, Shu‐han Sun – 13 December 2015 – Systemic analyses using large‐scale genomic profiles have successfully identified cancer‐driving somatic copy number variations (SCNVs) loci. However, functions of vast focal SCNVs in “protein‐coding gene desert” regions are largely unknown.

Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

Marta Cavallin, Salvatore Piano, Antonietta Romano, Silvano Fasolato, Anna Chiara Frigo, Gianpiero Benetti, Elisabetta Gola, Filippo Morando, Marialuisa Stanco, Silvia Rosi, Antonietta Sticca, Umberto Cillo, Paolo Angeli – 13 December 2015 – In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluses. To date, these two approaches have never been compared.

Identification of p38 MAPK and JNK as new targets for correction of Wilson disease‐causing ATP7B mutants

Giancarlo Chesi, Ramanath N. Hegde, Simona Iacobacci, Mafalda Concilli, Seetharaman Parashuraman, Beatrice Paola Festa, Elena V. Polishchuk, Giuseppe Di Tullio, Annamaria Carissimo, Sandro Montefusco, Diana Canetti, Maria Monti, Angela Amoresano, Piero Pucci, Bart van de Sluis, Svetlana Lutsenko, Alberto Luini, Roman S. Polishchuk – 13 December 2015 – Wilson disease (WD) is an autosomal recessive disorder that is caused by the toxic accumulation of copper (Cu) in the liver.

Identification of p38 MAPK and JNK as new targets for correction of Wilson disease‐causing ATP7B mutants

Giancarlo Chesi, Ramanath N. Hegde, Simona Iacobacci, Mafalda Concilli, Seetharaman Parashuraman, Beatrice Paola Festa, Elena V. Polishchuk, Giuseppe Di Tullio, Annamaria Carissimo, Sandro Montefusco, Diana Canetti, Maria Monti, Angela Amoresano, Piero Pucci, Bart van de Sluis, Svetlana Lutsenko, Alberto Luini, Roman S. Polishchuk – 13 December 2015 – Wilson disease (WD) is an autosomal recessive disorder that is caused by the toxic accumulation of copper (Cu) in the liver.

MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma

Han‐Yue OuYang, Jing Xu, Jun Luo, Ru‐Hai Zou, Keng Chen, Yong Le, Yong‐Fa Zhang, Wei Wei, Rong‐Ping Guo, Ming Shi – 13 December 2015 – Although many staging classifications have been proposed for hepatocellular carcinoma (HCC), determining a patient's prognosis in clinical practice is a challenge due to the molecular diversity of HCC. We investigated the relationship between MEP1A, a candidate oncogene, and clinical outcomes of HCC patients; furthermore, we explored the role of MEP1A in HCC.

Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study

Marta Cavallin, Salvatore Piano, Antonietta Romano, Silvano Fasolato, Anna Chiara Frigo, Gianpiero Benetti, Elisabetta Gola, Filippo Morando, Marialuisa Stanco, Silvia Rosi, Antonietta Sticca, Umberto Cillo, Paolo Angeli – 13 December 2015 – In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluses. To date, these two approaches have never been compared.

Subscribe to